| Literature DB >> 27862300 |
A Zoia1, M Drigo2, C J Piek3, P Simioni4, M Caldin5.
Abstract
BACKGROUND: Ascitic fluids of horses and humans have fibrinolytic activity, independent of the underlying mechanism of fluid formation.Entities:
Keywords: Ascites; Canine; Fibrinogenolysis; Fibrinolysis
Mesh:
Substances:
Year: 2016 PMID: 27862300 PMCID: PMC5259633 DOI: 10.1111/jvim.14610
Source DB: PubMed Journal: J Vet Intern Med ISSN: 0891-6640 Impact factor: 3.333
Causes of ascites in 70 dogs
| Group 1 (n = 10) | Group 2 (n = 18) | Group 3 (n = 13) | Group 4 (n = 29) |
|---|---|---|---|
|
PLE (5) |
Right‐sided CHF (14): |
Neoplasia directly involving the abdominal wall or the intra‐abdominal organ serosal surfaces (5) |
Hemangiosarcoma (21) |
Group 1: transudates due to decreased colloid osmotic pressure; Group 2: transudates due to increased hydrostatic pressure; Group 3: exudates; Group 4: hemorrhagic ascites; CHF, congestive heart failure; PLE, protein losing enteropathy; PLN, protein losing nephropathy; PE, pericardial effusion.
Hematological and ascitic fluid characteristics in the 4 groups of dogs with ascites included in the study
| Group 1 (n = 10) | Group 2 (n = 18) | Group 3 (n = 13) | Group 4 (n = 29) | |
|---|---|---|---|---|
|
Blood Hct (%) | 41.5 (19.2–69.8) | 40.5 (14.0–67.0) | 43.8 (24.0–59.4) | 28.9 (13.4–53.2) |
|
Serum TP (g/dL) | 3.1 (2.2–3.9) | 5.0 (4.2–6.2) | 6.2 (4.4–7.5) | 5.8 (4.2–7.7) |
|
Serum Albumin (g/dL) | 1.3 (0.9–1.4) | 2.5 (1.4–2.8) | 2.5 (1.8–3.1) | 2.8 (1.5–3.8) |
|
Ascitic Hct (%) | 0.0 (0.0–0.1) | 0.1 (0.0–2.2) | 0.7 (0.2–9.4) | 29.8 (7.9–45.8) |
|
Ascitic TP (g/dL) | 0.2 (0.1–0.4) | 3.5 (0.1–5.4) | 3.7 (1.8–5.1) | 5.1 (3.1–8.0) |
|
Ascitic TNCC (103 μL) | 0.19 (0.02–0.86) | 0.33 (0.01‐ 1.17) | 28.06 (2.30–173.55) | 11.12 (3.10–33.80) |
Group 1: transudates due to decreased colloid osmotic pressure; Group 2: transudates due to increased hydrostatic pressure; Group 3: exudates; Group 4: hemorrhagic ascites; Hct, hematocrit; TP, total protein; TNCC, total nucleated cell count.
Figure 1Box‐and‐whisker plots of plasma and ascitic fibrinogen concentrations in samples obtained from all the 70 dogs included in the study. Ascitic fibrinogen concentrations (median = 59 mg/dL; range: 59–60 mg/dL) were significantly (P < .0001) lower than plasma fibrinogen concentrations (median = 168 mg/dL; range: 59–879 mg/dL). For each box, the horizontal line represents the median value and lower, and upper boundaries represent 25th and 75th percentiles, respectively. Whiskers represent the most extreme observation that are not outliers. White circles represent outlier values (more than 1.5 interquartile range away from the closest end of the box), and black stars represent extreme outlier values (more than 3 interquartile range away from the closest end of the box).
Comparison of ascitic and plasma concentrations of fibrin–fibrinogen degradation products (FDPs)
| FDPs (μg/mL) | Ascites (n [%] of Dogs) | Plasma (n [%] of Dogs) |
|---|---|---|
| <5 | 3 (4.3) | 17 (24.3) |
| ≥5 to <20 | 10 (14.3) | 28 (40.0) |
| ≥20 | 57 (81.4) | 25 (35.7) |
Figure 2Box‐and‐whisker plots of plasma and ascitic D‐dimer concentrations in samples obtained from all the 70 dogs included in the study. Ascitic D‐dimer concentrations were significantly (P < .0001) higher (median: 3.98 μg/mL; range: 0.02–9.19) than plasma D‐dimer concentrations (median: 0.11 μg/mL; range: 0.01–4.08). For each box, the horizontal line represents the median value, and lower and upper boundaries represent 25th and 75th percentiles, respectively. Whiskers represent the most extreme observation that are not outliers. White circles represent outlier values (more than 1.5 interquartile range away from the closest end of the box), and black stars represent extreme outlier values (more than 3 interquartile range away from the closest end of the box).
Concentrations of fibrinogen, D‐dimer, and FDPs in ascites and plasma for 70 dogs with ascites
| Parameter | Ascites | Plasma |
| ||
|---|---|---|---|---|---|
| Group 1 (n = 10) |
Fibrinogen (mg/dL) | 59 (59–59) | 344 (79–774) | .005 | |
|
D‐dimer (μg/mL) | 1.68 (0.44–5.65) | 0.05 (0.01–0.72) | .005 | ||
| FDPs (μg/mL) | <5 | n = 2 | n = 7 | ||
| ≥5 to <20 | n = 5 | n = 2 | .079 | ||
| ≥20 | n = 3 | n = 1 | |||
| Group 2 (n = 18) |
Fibrinogen (mg/dL) | 59 (59–72) | 164 (60–678) | <.0001 | |
|
D‐dimer (μg/mL) | 2.55 (0.29–9.19) | 0.05 (0.01–0.78) | <.0001 | ||
| FDPs (μg/mL) | <5 | n = 1 | n = 1 | ||
| ≥5 to <20 | n = 2 | n = 14 | .0002 | ||
| ≥20 | n = 15 | n = 3 | |||
| Group 3 (n = 13) |
Fibrinogen (mg/dL) | 59 (59–122) | 327 (59–879) | .002 | |
|
D‐dimer (μg/mL) | 6.79 (0.02–8.71) | 0.15 (0.01–2.76) | .006 | ||
| FDPs (μg/mL) | <5 | n = 0 | n = 3 | ||
| ≥5 to <20 | n = 0 | n = 2 | .045 | ||
| ≥20 | n = 13 | n = 8 | |||
| Group 4 (n = 29) |
Fibrinogen (mg/dL) | 59 (59–59) | 157 (60–459) | <.0001 | |
|
D‐dimer (μg/mL) | 5.86 (0.10–9.05) | 0.26 (0.01–4.08) | <.0001 | ||
| FDPs (μg/mL) | <5 | n = 0 | n = 6 | ||
| ≥5 to <20 | n = 3 | n = 10 | .0008 | ||
| ≥20 | n = 26 | n = 13 |
Group 1: transudates due to decreased colloid osmotic pressure; Group 2: transudates due to increased hydrostatic pressure; Group 3: exudates; Group 4: hemorrhagic ascites; FDPs, fibrin–fibrinogen degradation products.